Recombinant Human VAP-1/AOC3 Protein (Fc Tag)

Catalog Number: PKSH033590



Note: Centrifuge before opening to ensure complete recovery of vial contents.

-					
- 1	00	cri	m	17	٦m
J			174	, T. U	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,

 Species
 Human

 Mol_Mass
 108.5 kDa

 Accession
 O16853

Bio-activity Not validated for activity

Properties

Purity > 95 % as determined by reducing SDS-PAGE.

Endotoxin < 1.0 EU per µg of the protein as determined by the LAL method.

Storage Generally, lyophilized proteins are stable for up to 12 months when stored at -20 to -80

°C. Reconstituted protein solution can be stored at 4-8°C for 2-7 days. Aliquots of

reconstituted samples are stable at < -20°C for 3 months.

ShippingThis product is provided as lyophilized powder which is shipped with ice packs.FormulationLyophilized from a 0.2 μm filtered solution of 20mM Tris-HCl, 500mM NaCl, pH 8.0.


Normally 5% - 8% trehalose, mannitol and 0.01% Tween 80 are added as protectants

before lyophilization.

Please refer to the specific buffer information in the printed manual.

Reconstitution Please refer to the printed manual for detailed information.

Data



> 95 % as determined by reducing SDS-PAGE.

Background

Membrane primary amine oxidase(AOC3); also known as vascular adhesion protein (VAP-1) and HPAO; this protein is a member of the semicarbazide-sensitive amine oxidase (SSAO) family. VAP-1 is a type 1 membrane-bound glycoprotein that has a distal adhesion domain and an enzymatically active amine oxidase site outside of the membrane; VAP-1 has adhesive properties; functional monoamine oxidase activity; and possibly plays a role in glucose handling; leukocyte trafficking; and migration during inflammation. This rise in metabolic products contributes to generating advanced glycation end-products and oxidative stress along with the monoamine detoxification in the organism. It is highly expressed on the endothelium of the lung and trachea; and absent from leukocytes and epithelial cells. Membrane-bound VAP-1 releases an active; soluble form of the protein; which may be conducive to increased inflammation and the progression of many vascular disorders. In particular; elevation of VAP-1 activity and the increased enzymatic-mediated deamination is proposed to play a role in renal and vascular disease; oxidative stress; acute and chronic hyperglycemia; and diabetes complications.

For Research Use Only